Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 January 2020 | Story Rulanzen Martin | Photo Pexels
Conference
At the meet-and-greet last night, were from left Prof Ruad Ganzevoort, Diversity Officer and Dean of Theology and Religion at VUA, Prof Francis Petersen and Dr Gene Block, Chancellor of UCLA.

The Unit for Institutional Change and Social Justice at the University of the Free State (UFS) is hosting a colloquium on Fragility and Resilience: Facets, Features and Transformation in Higher Education which started on 29 January, with the official progamme concluding on 30 January 2020.

The colloquium is a annual collaborative partnership between the UFS, University of California, Los Angeles (UCLA), and the Vrije Universiteit Amsterdam (VUA).

Apart from the overarching themes the colloquium also placed some focus on mental health, within this context as all three regions are witnessing a spike in mental health issues among students and staff as well as a deficit in terms of being able to sufficiently address the crisis.

“All three universities are committed to discussing global developments in diversity and transformation in higher education to discussing global developments in diversity and transformation as it may constitute itself in higher education circles around the globe,” says Dr Dionne van Reenen, convener of the 2020 colloquium and research fellow at the unit.  

The idea is to discuss what has and has not worked and, hopefully, access best practices in a variety of contexts. The partnership between the three universities spans over six years starting in 2014 when the UFS first hosted the research colloquium. It is the third time the UFS has hosted the colloquium.
 
Prof Francis Petersen, Rector and Vice-Chancellor of the UFS, along with other members of the UFS Rectorate, attended a meet-and-greet on Monday 28 January 2020, and was joined by Dr Gene Block, Chancellor of UCLA, Vice Provosts Cindy Fan, Patricia Turner, Charles Alexander, Professors Abel Valenzuela, John Hamilton and Dr Shalom Staub, director of Community Learning, as well as Prof Ruard Ganzevoort, Chief Diversity Officer and Dean of Theology and Religion at VUA 

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept